Alexander Chang, MD
Internal Medicine · San Francisco, CANPI 1225356231
Payments from drug & device makers
Across 94 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$352
- Johnson & Johnson$314
- Amarin Pharma, Inc.$227
- AstraZeneca$219
- Pfizer$200
- Gilead$185
- plus $732 from 13 others
What the payments were for
- Food & beverage$2,228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $352 |
| Johnson & Johnson | 16 | $314 |
| Amarin Pharma, Inc. | 14 | $227 |
| AstraZeneca | 3 | $219 |
| Pfizer | 9 | $200 |
| Gilead | 12 | $185 |
| SPR Therapeutics, Inc | 1 | $154 |
| GSK | 4 | $84 |
| AbbVie(2 entities) | 5 | $84 |
| Novo Nordisk | 4 | $81 |
| Amgen | 3 | $67 |
| Merck | 3 | $53 |
| Bardy Diagnostics, Inc. | 2 | $51 |
| Boehringer Ingelheim | 2 | $38 |
| Exact Sciences | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $30 |
| Edwards Lifesciences | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Artivion, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRINT PNS System$154
- AIRSUPRA$125
How this compares
$2,228 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 72 | $97,947 |
| TrulicityDulaglutide | 59 | $73,767 |
| JanuviaSitagliptin Phosphate | 48 | $52,896 |
| RybelsusSemaglutide | 18 | $49,854 |
| EliquisApixaban | 29 | $47,098 |
| OzempicSemaglutide | 29 | $40,763 |
| TymlosAbaloparatide | 13 | $33,157 |
| XareltoRivaroxaban | 27 | $28,979 |
| FarxigaDapagliflozin Propanediol | 21 | $27,660 |
| VemlidyTenofovir Alafenamide | 14 | $20,303 |
| EdarbiAzilsartan Medoxomil | 22 | $10,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,661 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $9,492 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,632 |
| Atorvastatin Calcium | 518 | $5,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $38 | $105,57988 claims |
| Novo NordiskRybelsus, Ozempic | $81 | $90,61747 claims |
| Lilly USA, LLCTrulicity | $352 | $73,76759 claims |
| MerckJanuvia | $53 | $52,89648 claims |
| PfizerEliquis | $200 | $47,09829 claims |
| Johnson & JohnsonXarelto | $314 | $28,97927 claims |
| AstraZenecaFarxiga | $219 | $27,66021 claims |
| GileadVemlidy | $185 | $20,30314 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $84 | $19,15334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.